Skip to main content

Table 2 Duration of Severe Neutropenia

From: Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy

  RGB-02 Reference Difference(RGB-02 - Reference)
Cycle 1, PP population
 n 112 111  
 Mean (SD) 1.7 (1.14) 1.6 (1.31)  
 Least squares mean (95% CI) 1.5 (1.2, 1.8) 1.4 (1.1, 1.7) 0.1 (−0.2, 0.4)
Cycle 1, FAS
 n 121 117  
 Mean (SD) 1.8 (1.28) 1.7 (1.45)  
 Least squares mean (95% CI) 1.6 (1.3, 1.9) 1.4 (1.1, 1.7) 0.1 (−0.2, 0.4)
Cycle 2, PP population
 n 111 100  
 Mean (SD) 0.7 (0.81) 0.7 (0.97)  
 Least squares mean (95% CI) 0.7 (0.4, 0.9) 0.6 (0.4, 0.8) 0.1 (−0.2, 0.3)
Cycle 2, FAS
 n 117 116  
 Mean (SD) 0.7 (0.81) 0.9 (1.31)  
 Least squares mean (95% CI) 0.5 (0.3, 0.8) 0.8 (0.5, 1.0) -0.2 (−0.5, 0.1)